Table 4.
Stability of Nemonoxacin in Spiked Plasma, Bile and Post-Preparative Samples
| Conditions | Plasma- % Remained (mean ± SD, n = 4) | Bile- % Remained (mean ± SD, n = 3) | ||||
|---|---|---|---|---|---|---|
| 5 ng/mL | 10 ng/mL | 250 ng/mL | 2000 ng/mL | 0.1 μg/mL | 5 μg/mL | |
| Bench-top stability (20 °C, 4 h) | 110.8±4.4 | 104.1±1.9 | 110.2±3.9 | 105.5±5.5 | 94.6±4.8 | 98.8±0.6 |
| Short-term stability (4 °C, 24 h) | 102.6±3.3 | 104.4±3.5 | 109.6±2.2 | 105.4±3.8 | 101.0±3.6 | 100.3±0.6 |
| Long-term stability (−20 °C) | ||||||
| 1 Day | 111.4±2.9 | 102.7±3.1 | 109.7±0.6 | 100.7±4.6 | 109.1±7.8 | 100.8±0.2 |
| 4 Days | 106.0±5.4 | 101.7±5.0 | 109.5±2.8 | 102.1±1.4 | 94.5±3.8 | 98.4±1.7 |
| 7 Days | 105.1±7.1 | 98.3±5.2 | 109.4±2.8 | 100.4±3.4 | 99.1±1.5 | 102.8±2.4 |
| 14 Days | 105.2±5.6 | 100.4±2.6 | 102.8±2.2 | 99.0±2.3 | 102.8±6.3 | 99.1±0.6 |
| 28 Days | 97.5±5.4 | 94.3±3.7 | 96.1±0.4 | 104.0±5.3 | 96.0±5.1 | 104.7±2.6 |
| Freeze-thaw stability (−20 °C/20 °C) | ||||||
| Cycle 1 | 107.6±2.6 | 104.6±6.0 | 109.7±0.8 | 106.0±2.4 | 97.6±3.5 | 104.1±3.5 |
| Cycle 2 | 109.0±0.8 | 106.3±5.4 | 110.7±0.9 | 106.7±2.3 | 96.9±3.6 | 102.6±2.7 |
| Cycle 3 | 103.1±7.3 | 99.1±3.9 | 96.9±2.3 | 94.7±2.5 | 108.1±1.8 | 99.6±3.0 |
| Post-preparative stability (−20 °C, 24 h) | 107.9±1.5 | 109.2±2.5 | 109.5±0.5 | 105.9±3.1 | 102.2±2.8 | 94.1±2.6 |